Literature DB >> 6084786

Alpha 2-agonist activity of the dopamine DA2-agonist LY171555.

M L Cohen, C J Shaar, W E Colbert.   

Abstract

LY171555 is the active enantiomer of the racemate LY141865, a selective DA2-receptor agonist. LY171555 (10(-7)-10(-4) M) inhibited the twitch response to field stimulation in the adrenergically innervated rat vas deferens, a response due to activation of alpha 2-receptors as evidenced by total blockade with yohimbine (10(-6) M). The dopamine receptor antagonist sulpiride (10(-5) M) produced a small shift in the concentration-response curve to LY171555, consistent with the modest alpha 2-antagonist activity of sulpiride. LY171555 (10(-10)-10(-8) M) inhibited prolactin release from the anterior pituitary in vitro, a response due to activation of DA2-receptors as indicated by total blockade with sulpiride (10(-6) M). Thus, in addition to its predominant DA2-agonist activity, LY171555 can activate alpha 2-receptors in concentrations similar to those necessary for activation of histamine H2-receptors. Such concentrations were approximately 2,250-fold higher than necessary for DA2-receptor activation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6084786

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Effects of the novel dopamine DA2-receptor agonist carmoxirole (EMD 45609) on noradrenergic and purinergic neurotransmission in rat isolated kidney.

Authors:  L C Rump; K Wilde; C Bohmann; P Schollmeyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

2.  Monoamines modulate the electrically-evoked efflux of 3H-choline from slices of guinea pig nucleus basalis magnocellularis.

Authors:  A Siniscalchi; I Badini; C Bianchi; L Beani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

3.  Modulation of [3H]-dopamine released by different frequencies of stimulation from rabbit retina.

Authors:  M L Dubocovich; J G Hensler
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.